HealthQuill Novo Nordisk
Eli Lilly, a US company that forecasts revenue of up to $33.9 billion, plans to build a $2.5 billion plant in Germany to make devices for treating diabetes and obesity.
Drugs Health Pharma

Novo Nordisk buys 3 Catalent sites for $11bn to meet rising demand for Wegovy

HQ Team February 5, 2024: Novo Nordisk will acquire three manufacturing sites in an $11bn deal to expand its production of weightless drugs.

Read More
Denmark’s Novo Nordisk declared its late-stage experimental once-weekly diabetes drug IcoSema achieved its primary endpoint of proving “non-inferiority” in lowering blood sugar levels.
Drugs Health Pharma

Novo Nordisk diabetes drug meets trial goals against insulin glargine

 HQ Team January 9, 2023: Denmark’s Novo Nordisk declared its late-stage experimental once-weekly diabetes drug IcoSema achieved its primary endpoint of proving “non-inferiority” in.

Read More
The FDA has seized “thousands of units” of counterfeit weight-loss injection Ozempic which have no information about the drug’s identity, quality or safety.
Drugs Health Pharma

FDA starts crackdown against fake Ozempic weight-loss drug 

HQ Team December 22, 2023: The FDA has seized “thousands of units” of counterfeit weight-loss injection Ozempic which have no information about the.

Read More
Semaglutide based weightloss drugs tied to increased suicide risk in a new study
Drugs Health Pharma

EMA expands probe into suicidal thoughts linked to weight loss drugs

HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.

Read More
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Medical Pharma

Eli Lilly’s Zepbound outperforms Novo’s Wegovy in weight loss study

HQ team November 28, 2023: A recent comparative analysis of Eli Lilly and Novo Nordisk’s weight loss drugs on diabetes patients showed Eli.

Read More
— at a time when President Emmanuel Macron is taking steps to stem the country’s industrial decline.
Drugs Health Pharma

Novo Nordisk invests $2.3b in France for diabetes, obesity drugs

HQ Team November 23, 2023: Novo Nordisk will invest $2.3 billion to expand production of its weight-loss and diabetes drug in Chartes, France..

Read More
Novo Nordisk plans to invest 42 million Danish kroner ($6 billion) in Denmark to create new capacities for making active pharmaceutical ingredients and expand its portfolio within serious chronic diseases.
Drugs Health Pharma

Novo Nordisk plans $6 billion investment to expand in Denmark

HQ Team November 10, 2023: Novo Nordisk plans to invest 42 million Danish kroner ($6 billion) in Denmark to create new capacities for.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Health Pharma

US, UK regulators give green light to Eli Lilly’s weight-loss treatment

HQ Team November 9, 2023: Eli Lilly’s weight-loss injection Zepbound, to be taken along as a supplement with diet and exercise, got the.

Read More
Drugs Health Pharma

Novo Nordisk to buy hypertension drug from KBP for $1.3 billion

HQ Team October 16, 2023: Danish pharmaceutical company, Novo Nordisk, announced it was buying a hypertension drug, still in trials, from Singapore-based KBP.

Read More